MNMD.Q

Not So Generalized Disorder “Anxiety is a part of normal life.” Or so I was told. Whether I was simply leaving my apartment to get food or speaking during…
$901.372M Market Capitalization Mind Medicine Inc. (MNMD.Q) today announced the initiation of a Phase 2a proof-of-concept (POC) trial of lysergic acid diethylamide (LSD) in adult patients with attention deficit…
Mind Medicine (MNMD.Q, MMED.NE) announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate…
MindMed (MNMD.Q) and healthcare data consolidator Datavant, announced a partnership wherein MindMed will make use of Datavant’s tech to link their clinical trial data to external data from both…
Big ass IPO? Not really… ‘Shares soar as Atai Life Sciences IPO’s on the Nasdaq’ is the story being spun around Atai’s (ATAI.Q) first crack at going public last…
Mind Medicine (MNMD.Q) announced the addition of Dr. Peter Bergethon to their Scientific Advisory Board. Bergethon is a “world-leading” expert in neurology, digital medicine, and central nervous system (CNS)…